Claims for Patent: 10,155,946

Summary for Patent: 10,155,946

Title:	Particle-nucleic acid conjugates and therapeutic uses related thereto
Abstract:	This disclosure relates to particles conjugated to therapeutic nucleic acids. In certain embodiments, the nucleic acid comprises a sequence that catalytically cleaves RNA, e.g., DNAzyme or RNAzyme. In certain embodiments, the particles contain nucleic acids with both DNAzyme and/or RNAzyme and siRNA sequences. The cleaving nucleic acids optionally comprise a sequence functioning to hybridize to a target of interest and/or the particles are further conjugated to a targeting moiety. In certain embodiments, conjugated particles are used in the treatment or prevention of cancer or viral infections or bacterial infections. In certain embodiments, conjugated particles are used in detecting metal ions and other small molecule analyte.
Inventor(s):	Yehl; Kevin (Atlanta, GA), Khalid; Salaita (Decatur, GA)
Assignee:	Emory University (Atlanta, GA)
Application Number:	15/728,474
Patent Claims:	1. A method of treating cancer comprising administering an effective amount of a pharmaceutical composition, to a subject in need thereof, wherein the pharmaceutical composition comprises particle conjugated to a catalytically cleaving nucleic acid; wherein the catalytically cleaving nucleic acid comprises a DNAzyme sequence having SEQ ID NO:1; wherein conjugation to the particle is through the 3' end of DNAzyme; and wherein the catalytically cleaving nucleic acid is conjugated to a cancer cell targeting moiety. 2. The method of claim 1 wherein the targeting moiety is an antibody that targets a tumor antigen. 3. The method of claim 1 wherein the targeting moiety is antibody to HER-2. 4. The method of claim 1 wherein the targeting moiety is an antibody to carcinoembryonic antigen. 5. The method of claim 1 wherein the targeting moiety is transferrin. 6. The method of claim 1 wherein the targeting moiety is folic acid. 7. hod of claim 1 wherein the targeting moiety is methotrexate. 8. The method of claim 1 wherein targeting moiety is luteinizing hormone releasing hormone. 9. The method of claim 1, wherein the targeting moiety is a nucleic acid sequence functioning to hybridize to a target of interest. 10. The method of claim 1, wherein the targeting moiety is a nucleic acid sequence that hybridizes to c-Jun mRNA. 11. The method of claim 1, wherein the targeting moiety is a nucleic acid sequence that hybridizes to LMP1 mRNA. 12. The method of claim 1, wherein the targeting moiety is a nucleic acid sequence that hybridizes to mRNA of human telomere reverse transcriptase. 13. The method of claim 1, wherein the targeting moiety is a nucleic acid sequence that hybridizes to survivin mRNA. 14. The method of claim 1, wherein the targeting moiety is a nucleic acid sequence that hybridizes to a translation initiation region of c-myc RNA. 15. The method of claim 1, wherein the cancer is selected from brain, lung, cervical, ovarian, colon, breast, gastric, skin, ovarian, pancreatic, prostate, neck, and renal cancer. 16. The method of claim 1, wherein, the pharmaceutical composition is administered in combination with a second anticancer agent. 17. The method of claim 16 wherein, the second anticancer agent may be selected from temozolamide, bevacizumab, procarbazine, lomustine, vincristine, gefitinib, erlotinib, docetaxel, cis-platin, 5-fluorouracil, gemcitabine, tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin, vinblastine, vindesine, vinorelbine, taxol, taxotere, etoposide, teniposide, amsacrine, topotecan, camptothecin, bortezomib, anagrelide, tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene, fulvestrant, bicalutamide, flutamide, nilutamide, cyproterone, goserelin, leuprorelin, buserelin, megestrol, anastrozole, letrozole, vorazole, exemestane, finasteride, marimastat, trastuzumab, cetuximab, dasatinib, imatinib, combretastatin, thalidomide, and/or lenalidomide or combinations thereof. 18. The method of claim 1, wherein the subject is exposed to electromagnetic radiation under conditions such that the administered particle releases nucleic acids conjugated to the particle.

Details for Patent 10,155,946

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2032-06-25
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2032-06-25
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2032-06-25
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2032-06-25
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-06-25